Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

MDElliottMD/Sandbox/CYP2C9: Difference between revisions

From Pharmacopedia
Expand CYP2C9 substrate section per Mark 2026-05-19 Option C decision: replace bullet list with 36-row sortable wikitable (substrate / therapeutic class / CYP2C9 contribution tier / clinical notes) covering anticoagulants, antiepileptics, NSAIDs, sulfonylureas, ARBs, statins, cannabinoids, antifungals, others. Add Comprehensive-tables pointer section naming Flockhart Indiana University table, FDA Drug Development table, PharmGKB (cited Whirl-Carrillo 2021 PMID 34216021). Add Zanger and Schwab...
Expand CYP2C9 substrate section per Mark 2026-05-19 Option C decision: replace bullet list with 36-row sortable wikitable (substrate / therapeutic class / CYP2C9 contribution tier / clinical notes) covering anticoagulants, antiepileptics, NSAIDs, sulfonylureas, ARBs, statins, cannabinoids, antifungals, others. Add Comprehensive-tables pointer section naming Flockhart Indiana University table, FDA Drug Development table, PharmGKB (cited Whirl-Carrillo 2021 PMID 34216021). Add Zanger and Schwab...
Line 12: Line 12:


{| class="wikitable sortable mw-collapsible mw-collapsed" style="width:100%;"
{| class="wikitable sortable mw-collapsible mw-collapsed" style="width:100%;"
|+ style="white-space:nowrap; text-align:left;" | CYP2C9 substrate table (click to expand)
|+ style="white-space:nowrap; text-align:left;" | near-complete CYP2C9 substrate table (click to expand)
! Substrate !! Therapeutic class !! CYP2C9 contribution !! Clinical notes
! Substrate !! Therapeutic class !! CYP2C9 contribution !! Clinical notes
|-
|-